Sandesh Seth, Actinium CEO

En route to BLA fil­ing, Ac­tini­um de­tails PhI­II win for tar­get­ed ra­dio­ther­a­py in acute myeloid leukemia

Ac­tini­um Phar­ma­ceu­ti­cals has spelled out the full Phase III da­ta for its lead tar­get­ed ra­dio­ther­a­py — one that ex­ecs say presents a “prac­tice ex­pand­ing op­por­tu­ni­ty” in acute myeloid leukemia.

In the SIER­RA tri­al, Ac­tini­um’s Iomab-B met the pri­ma­ry end­point by help­ing 22% of pa­tients achieve six-month durable com­plete re­mis­sion fol­low­ing ini­tial com­plete re­mis­sion af­ter a bone mar­row trans­plant — com­pared to 0% of the con­trol arm (p<0.0001).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.